Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1Unknown 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 103Lung Neoplasms 44Breast Neoplasms 41Triple Negative Breast Neoplasms 34Ovarian Neoplasms 28Small Cell Lung Carcinoma 26Squamous Cell Carcinoma of Head and Neck 23Fallopian Tube Neoplasms 18Endometrial Neoplasms 17Neoplasms 16Neoplasm Metastasis 13Head and Neck Neoplasms 13Uterine Cervical Neoplasms 12Esophageal Squamous Cell Carcinoma 12Prostatic Neoplasms 10Parkinson Disease 4, Autosomal Dominant Lewy Body 10Esophageal Neoplasms 10Colorectal Neoplasms 9Recurrence 8Carcinoma, Transitional Cell 8Oropharyngeal Neoplasms 7Carcinoma, Squamous Cell 7Neuroblastoma 6Carcinoma, Ovarian Epithelial 6Urinary Bladder Neoplasms 5Mesothelioma 5Lymphoma, Large B-Cell, Diffuse 5Lung Diseases 5Adenocarcinoma of Lung 5Thoracic Neoplasms 4

Interventions

Trastuzumab 8pyrotinib 6pertuzumab 4Docetaxel 3Capecitabine 3tucatinib 2Paclitaxel 2Neoadjuvant Therapy 2trastuzumab deruxtecan 1neratinib 1inavolisib 1Taxoids 1Isovaleryl-CoA Dehydrogenase 1Injections 1Genetic Testing 1Drug Therapy 1Carboplatin 1Blood Specimen Collection 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × HER2-positive Breast Cancer × Carboplatin × Clear all
NCT07043725 2026-03-27

A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Recruiting
544 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡